The Effect of Iloprost on Capillary Recruitment and Insulin Sensitivity in Type 2 Diabetes

The Effects of Iloprost Infusion on Capillary Recruitment and Whole-body Glucose Uptake in Type 2 Diabetic Patients - a Cross-over Trial.

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03380325

Enrollment

Registered

2017-12-21

Start date

2016-05-11

Completion date

2017-06-29

Last updated

2019-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 2, Insulin Sensitivity/Resistance

Keywords

Capillary recruitment

Brief summary

This study examines the effects of iloprost - a stable prostacyclin analogue - on insulin-mediated muscle capillary recruitment and whole-body glucose uptake in a cross-over design.

Detailed description

In type 2 diabetes impaired insulin-mediated muscle perfusion is thought to contribute to reduced whole-body glucose uptake. This study aims to identify iloprost - a stable prostacyclin analogue - as a possible therapeutic option to increase whole-body glucose uptake via enhancement of muscle perfusion. All participants will be subjected to two hyperinsulinemic-euglycemic clamps; one with and one without simultaneous iloprost infusion in a randomized cross-over design. Microvascular blood volume will be measured by means of contrast-enhanced ultrasonography.

Interventions

DRUGIloprost infusion

Iloprost is a stable prostacyclin analogue

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Type 2 diabetes * Male or female (post-menopausal) * Age above 45 years and below 70 years * BMI \>30 kg/m2 * HbA1c \< 80 mmol/mol or \< 8,6% Subjects must use metformin * Stable medication use * Stable tension regulation (with or without medication) * Subjects should be able to give informed consent

Exclusion criteria

* A history of cardiovascular event (Cerebrovascular event, myocardial infarction or pacemaker implantation) * Severe-very severe lung emphysema (GOLD stage III-IV) * Use of any antibiotics or proton pump inhibitor (PPI) in the past three months * Use of any other antidiabetic medication besides metformin (e.g. SU-derivates, insulin) * Use of a platelet inhibitor or cumarin derivate during * Subjects participated in a lifestyle programme in the past 6 months (diet or exercise)

Design outcomes

Primary

Measure	Time frame	Description
Rate of disappearance	During the clamp	Glucose uptake in peripheral tissues during hyperinsulinemic euglycemic clamp
Capillary recruitment	Before and during the clamp	Change in skeletal muscle en myocardial microvascular blood volume upon insulin infusion

Secondary

Measure	Time frame	Description
Continous cardiovascular monitoring	Before and during the clamp	Diastolic blood pressure

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026